Albany, NY -- (SBWIRE) -- 06/17/2020 -- Beta-thalassemia Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Beta-thalassemia Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. The total prevalent population of Beta-thalassemia in 6MM was 14,191 in 2017.
2. The total prevalent cases for Beta-thalassemia were highest in Italy, followed by the United States and Germany.
3. Endocrine complications and Osteoporosis was found in the majority of patients with Beta-Thalassemia.

Key benefits of the report
1. Beta-thalassemia market report covers a descriptive overview and comprehensive insight of the Beta-thalassemia epidemiology and Beta-thalassemia market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Beta-thalassemia market report provides insights into the current and emerging therapies.
3. Beta-thalassemia market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Beta-thalassemia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Beta-thalassemia market.

Request for sample pages

Beta Thalassemia is a genetic disorder which is inherited in an autosomal, recessive fashion. The clinical manifestations seen in patients are severe anaemia, abnormal haemoglobin and buildup of iron in the body. Being a genetic disorder, there is no specific treatment for Beta Thalassemia and the treatment regimen mainly focus on delaying progression of the disease and relieving the symptoms.

The main complication from frequent blood transfusions is iron overload, as the human body lacks a method of excreting excess iron. Iron accumulation, particularly in the heart, liver, and pituitary gland, can lead to heart failure, cirrhosis, hepatocellular carcinoma, hypothyroidism, hypoparathyroidism, hypogonadism, diabetes, and growth failure. Iron chelation therapy is the primary method of both treating and preventing iron overload. The primary goal of chelation is to maintain iron balance in the body by excreting excess iron through urine or faeces. Thus, owing to the symptomatic treatment in the target patient population, the current market of Beta Thalassemia covered in the report solely focuses on the market revenue generated by iron binders/chelators.
There are some iron chelators used in iron chelation therapies, namely: Deferoxamine (DFO), Deferiprone (DFP) and Deferasirox (DFX). These are either given alone or in combination, Desferal (deferoxamine mesylate USP), developed by Novartis.

Desferal is indicated for the treatment of acute iron intoxication and of chronic iron overload due to transfusion-dependent anaemia. Desferal can promote iron excretion in patients with secondary iron overload from multiple transfusions—as may occur in the treatment of some chronic anaemias, including thalassemia. Besides, it can be given by intramuscular, subcutaneous, and intravenous routes of administration.

Novartis developed Exjade (Deferasirox), which is an oral iron chelator approved by the US FDA in 2005. It is a member of a new class of tridentate iron chelators, the N-substituted bis-hydroxyphenyl-triazoles. Metabolism and elimination of deferasirox are primarily by glucuronidation followed by hepatobiliary excretion into the faeces. Approved in more than 70 countries including the US and Europe, Exjade is the first once-daily oral iron chelator approved for use in patients with chronic transfusional iron overload who have a wide range of underlying anaemias.

The launch of the emerging therapies is expected to significantly impact the Beta-thalassemia treatment scenario in the upcoming years:-
Drugs covered
1 LentiGlobin BB305
2 PTG-300
3 ACE-011 (Sotatercept)
4 Mitapivat
5 IONIS TMPRSS6 LRx
6 VIT 2763
7 Emeramide
And many others

The key players in Beta-thalassemia market are:
1. BlueBird Bio
2. Protagonist Therapeutics
3. Acceleron Pharma
4. Celgene Corporation
5. Agios Pharmaceuticals
6. Ionis Pharmaceuticals
7. Vifor Pharma
8. EmeraMed
And many others

Table of contents
1 Key Insights
2 Executive Summary of Beta Thalassemia
3 SWOT Analysis for Beta Thalassemia
4 Beta Thalassemia Market Overview at a Glance
5 Beta-thalassemia Disease Background and Overview
6 Beta-thalassemia Epidemiology and Patient Population
7 Country Wise-Epidemiology of Beta Thalassemia
7.1 The United States
7.2 EU5 Countries
7.2.1 Germany
7.2.2 France
7.2.3 Italy
7.2.4 Spain
7.2.5 The UK
7.3 Japan
8 Beta-thalassemia Treatment and Management
9 Case Study
10 Unmet Needs
11 Beta-thalassemia Marketed Products
11.1 Desferal: Novartis
11.2 Exjade: Novartis
11.3 Ferrirpox (deferiprone): Apotex
11.4 ACE-536: Acceleron Pharma/Celgene Corporation
12 Beta-thalassemia Emerging Therapies
12.1 LentiGlobin BB305: BlueBird Bio
12.2 PTG-300: Protagonist Therapeutics
12.3 ACE-011 (Sotatercept): Acceleron Pharma/Celgene Corporation
12.4 Mitapivat: Agios Pharmaceuticals
12.5 IONIS TMPRSS6 LRx: Ionis Pharmaceuticals
12.6 VIT 2763: Vifor Pharma
12.7 Emeramide: EmeraMed
13 Other Promising Candidates
13.1 OTL-300: Orchard Therapeutics
13.2 ST-400: Sangamo Therapeutics/Sanofi
13.3 CTX001: CRISPR Therapeutics/Vertex Pharmaceuticals
14 Other Products in the News
14.1 DST-0509 : DisperSol Technologies
14.2 ATIR201: Kiadis
14.3 Ruxolitinib: Incyte Corporation/ Novartis
14.4 EDIT-301: Editas Medicine
14.5 Global Blood Therapeutics/ Syros Pharmaceuticals
15 Discontinued Therapies
15.1 LJPC-401: La Jolla Pharmaceutical Company
16 Beta Thalassemia: 6 Major Market Analysis
17 Beta-thalassemia Market Outlook by Country
17.3 Germany Market Size
17.4 France Market Size
17.5 Italy Market Size
17.6 Spain Market Size
17.7 The UK Market Size
18 Market Access and Reimbursement Landscape
19 Market Drivers
20 Market Barriers
21 Appendix
22 DelveInsight Capabilities
23 Disclaimer
24 About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight